The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase 3 trial of APF530 versus palonosetron (PALO) in preventing chemotherapy-induced nausea and vomiting (CINV): Efficacy in breast cancer patients (pts) receiving moderately (MEC) or highly (HEC) emetogenic chemotherapy.
Ralph V. Boccia
No relevant relationships to disclose
William Cooper
Consultant or Advisory Role - TFS
Erin O'Boyle
Consultant or Advisory Role - A.P. Pharma
Stock Ownership - A.P. Pharma